Your browser doesn't support javascript.
loading
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer.
Adam, Salomé; Rossi, Silvia Emma; Moatti, Nathalie; De Marco Zompit, Mara; Xue, Yibo; Ng, Timothy F; Álvarez-Quilón, Alejandro; Desjardins, Jessica; Bhaskaran, Vivek; Martino, Giovanni; Setiaputra, Dheva; Noordermeer, Sylvie M; Ohsumi, Toshiro K; Hustedt, Nicole; Szilard, Rachel K; Chaudhary, Natasha; Munro, Meagan; Veloso, Artur; Melo, Henrique; Yin, Shou Yun; Papp, Robert; Young, Jordan T F; Zinda, Michael; Stucki, Manuel; Durocher, Daniel.
Afiliação
  • Adam S; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Rossi SE; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Moatti N; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • De Marco Zompit M; Department of Gynecology, University Hospital and University of Zurich, Schlieren, Switzerland.
  • Xue Y; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Ng TF; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Álvarez-Quilón A; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Desjardins J; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Bhaskaran V; Repare Therapeutics, St-Laurent, Quebec, Canada.
  • Martino G; Repare Therapeutics, St-Laurent, Quebec, Canada.
  • Setiaputra D; Repare Therapeutics, St-Laurent, Quebec, Canada.
  • Noordermeer SM; Repare Therapeutics, St-Laurent, Quebec, Canada.
  • Ohsumi TK; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Hustedt N; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Szilard RK; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Chaudhary N; Repare Therapeutics, St-Laurent, Quebec, Canada.
  • Munro M; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Veloso A; Lonza AG, Visp, Switzerland.
  • Melo H; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Yin SY; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Papp R; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Young JTF; Repare Therapeutics, St-Laurent, Quebec, Canada.
  • Zinda M; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Stucki M; Repare Therapeutics, St-Laurent, Quebec, Canada.
  • Durocher D; Repare Therapeutics, St-Laurent, Quebec, Canada.
Nat Cancer ; 2(12): 1357-1371, 2021 12.
Article em En | MEDLINE | ID: mdl-35121901
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mutações Sintéticas Letais / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mutações Sintéticas Letais / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá